Skip to main content

Table 1 Annual first infection rate, reinfection rate, and HCV treatment coverage observed in the Dat'AIDs cohort between 2012 and 2016

From: Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

 

MSM (low-risk/high-risk)

Heterosexuals

IVDU

Others

2012

 First infection rate (per 100 py)

0.02/1.84

0.01

0

0.09

 Reinfection rate (per 100 py)

0.22a/2.56c

0.24b

0.16b

0.27b

 HCV treatment rate (%)

13.4

6.9

6.8

10.9

2013

 First infection rate (per 100 py)

0.06/2.23

0.03

0

0.29

 Reinfection rate (per 100 py)

0.22a/2.56c

0.24b

0.16b

0.27b

 HCV treatment rate (%)

4.4

11.0

5.1

7.6

2014

 First infection rate (per 100 py)

0.12/2.40

0.07

2.13

0.23

 Reinfection rate (per 100 py)

0.22a/2.56c

0.24b

0.16b

0.27b

 HCV treatment rate (%)

10.5

14.0

17.1

23.0

2015

 First infection rate (per 100 py)

0.09/3.42

0.05

1.69

0.17

 Reinfection rate (per 100 py)

0.22a/2.56c

0.24b

0.16b

0.27b

 HCV treatment rate (%)

27.6

36.0

27.0

33.8

  1. aMean yearly reinfection rate observed in non-MSM risk groups between 2012 and 2015
  2. bMean yearly reinfection rate observed in heterosexuals, IVDU, and others risk groups between 2012 and 2015
  3. cMean yearly reinfection rate observed in MSM between 2012 and 2015
  4. HCV hepatitis C virus, IVDU intravenous drug users, MSM men who have sex with men, py person-year